Introduction
Protein encoding genes of the human genome are composed of multiple exons interrupted by introns. Exons consist of 50-250 base pairs, while introns are usually larger and can comprise up to several thousand base pairs. In general, exon sequences encode for proteins, whereas introns are generally non-coding. During gene transcription, exon and intron sequences are converted into single precursor messenger ribonucleic acid (pre-mRNA). In a process called "splicing", intron sequences are removed from pre-mRNA and exons are fused together resulting in the formation of mature mRNA, which is processed further and subsequently transported out of the nucleus into the cellular cytoplasm to be translated into proteins. Most genes give rise to multiple spliced transcripts by a process called alternative splicing.
These various transcripts contain different combinations of exons, leading to different mRNA variants and the synthesis of different proteins. Alternative splicing can, amongst others, induce the formation of a large number of different oncoproteins. The spliceosome, an intracellular complex of multiple proteins and ribonucleoproteins, is the main cellular machinery guiding splicing. Recently, two natural compounds interfering with the spliceosome were found to display antitumor activity in vitro and in vivo (1) (2) (3) . Therefore, it is conceivable that inhibiting the spliceosome could serve as a novel target for the development of anticancer drugs (4-6).
E7107, a first-in-class spliceosome inhibitor, is a semi-synthetic derivative of the natural product pladienolide B, originally isolated from Streptomyces platensis, which strongly inhibits hypoxia-induced vascular endothelial growth factor expression and stable in aqueous solution at around pH 6. Recent studies indicate that E7107 inhibits activity of the spliceosome most likely by interacting with the spliceosome-associated protein-130 (7) (8) (9) (10) . The result of this interaction is that E7107 modulates "maturation" processing of pre-mRNA to mRNA, with consequent changes in protein expression profiles. E7107 has shown the most activity against tumors that express a functional loss of retinoblastoma gene, an increased p16 expression, and upregulated cyclin E (10). In cell-based assays, E7107 inhibits proliferation of a panel of eight human tumor cell lines with half maximal inhibitory concentration of 1.0-20 nmol/L.
Most human xenograft tumors tested, including lung, breast, and colon carcinomas, responded to treatment with E7107 with tumor regression (mT/C <42%) (8).
Pharmacokinetic (PK) studies in mice, rats, and dogs indicated a large distribution volume, high plasma clearance, and linear increase in overall drug exposure (area under the curve) when the dose was increased. CYP3A4 appears to metabolize E7107, but other cytochromes as yet uncharacterized may be involved as well (Eisai, data on file).
We performed this first-in-man phase I PK and pharmacodynamic (PD) study of E7107 administered intravenously as a 5-minute bolus infusion on days 1, 8, and 15 in a 28-day schedule. The objectives of this study were to: identify dose-limiting toxicities (DLTs) of E7107; explore the safety and tolerability of E7107; determine the PK profile of E7107; determine biomarkers of the PD effect and potential efficacy by identifying changes in pre-and mRNA expression in peripheral blood cells; and explore the antitumor activity of E7107.
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Patients and Methods

Eligibility criteria
Main inclusion criteria (full description in the Supplementary text) were histologically confirmed advanced tumors, unresponsive to standard therapy; age >18 years; life expectancy >3 months; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and adequate bone marrow, hepatic, and renal function. All patients gave written informed consent prior to any study-related procedure and approval was obtained from the ethics committees at the participating institutions and regulatory authorities. The study followed the Declaration of Helsinki and good clinical practice guidelines.
Pretreatment and follow-up examinations
Prior to therapy, a complete medical history was taken and a physical examination was performed. A complete blood cell count (CBC), including white blood cell (WBC) differential and serum biochemistry, was performed, as were urinalysis and chest X-ray. A 12-lead electrocardiogram (ECG) was made at screening, pre-infusion, within 1 hour post-infusion at days 1, 8, and 15 (Cycles 1 and 2 only), and at study termination. Weekly evaluations included physical examination and vital signs, adverse events (AEs) and ECOG performance status assessment, CBC including WBC differential and serum chemistry. Patients were evaluated for AEs and toxicity according to the National Cancer Institute Common Toxicity Criteria, Version 3.0.
Tumor measurements were performed prior to enrollment and every other cycle.
Response was assessed using Response Evaluation Criteria in Solid Tumors
Research. (RECIST) (11). Patients were allowed to continue treatment in the absence of progressive disease or unacceptable toxicity.
Drug administration and dose-escalation procedure
E7107 was administered intravenously as 5-minute bolus infusions for 3 consecutive weeks in a 28-day schedule. Based on animal toxicology data, the starting dose was 0.6 mg/m 2 , which corresponds with one-tenth of the dose inducing severe toxicity or death in rats, the most sensitive species in toxicology studies. Patients were enrolled sequentially into escalating dosing cohorts using a standard 3+3 Fibonacci-modified design. Dose increases in subsequent cohorts were by approximately 100%
increments until a patient at a given dose level experienced toxicity of Grade 2 or higher. From then on, dose increases were by 50% or less, depending upon the seriousness of the toxicity. Intra-patient dose escalation was not allowed.
DLT was defined as any Grade-3-4 hematological toxicity with the exception of neutropenia lasting fewer than 7 days and lymphopenia; any Grade-3 or higher nonhematological toxicity considered to be treatment-related, with the exceptions of nausea and vomiting in the absence of appropriate antiemetics and diarrhea recovering within 12 hours. In addition, any repeated Grade-2 hematological or nonhematological toxicity considered to be directly related to E7107 and requiring dose reduction was considered DLT, as was delayed recovery from toxicity related to treatment delaying scheduled re-treatment for >14 days and toxicities requiring dose reductions during Cycle 1. Finally, an ECG demonstrating QTc interval >500 msec while on therapy or 60 msec increase over baseline was considered DLT.
The maximum tolerable dose (MTD) was defined as the highest dose level that could be given to six patients with no more than one patient experiencing DLT. If during dose escalation one in three patients experienced DLT during Cycle 1, an additional three patients were to be treated at that dose level. If no additional DLT was observed, dose escalation could be continued until MTD was reached. Once the MTD was established, this cohort was to be expanded with 10 more patients, in order to have a minimum of 15 fully evaluable patients and to achieve a more complete description of the safety and PK profile.
Pharmacokinetic evaluation
Complete PK evaluation was performed by collecting blood samples via an indwelling intravenous catheter in the opposite arm of the infusion. In Cycle 1, on days 1 and 15, 4 mL samples were collected pre-dose, at the end of infusion, at 5, 10, PK parameters included the peak plasma concentration (C max ), area under the plasma concentration-time curve extrapolated to infinity (AUC 0-∞ ), total body clearance from plasma (CL), volume of distribution at steady state (V ss ), and terminal phase elimination half-life (t ½ ). Plasma concentrations were measured using a validated liquid chromatography-tandem mass spectrometry technique. The lower limit of quantification of the analytical method of each compound was 0.01 ng/mL for plasma.
Pharmacodynamic analysis
To investigate the effect of E7107 on levels of mature mRNA and unspliced premRNA, the expression of certain specific candidate genes was examined in peripheral blood mononuclear cells (PBMCs). The candidate genes were determined using exon array and qRT-PCR analysis of human and animal tissues and cell lines. Genes were selected for inclusion in this analysis based upon the presence of detectable changes at early time points following exposure, durability of the changes in expression, and detectability in multiple tissues and cell lines. Blood samples (3 mL) were taken preinfusion and 2, 6, 24, and 48 hours relative to end of bolus infusion in Cycle 1 at days 1 and 15, and an additional pre-infusion sample was taken at day 1 of Cycle 2. Blood samples were collected at these 11 time points, total RNA was isolated and reversedtranscribed, after which the pre-and mRNA expression levels of selected target genes by real-time PCR were determined (12). A more detailed description of this analysis and the candidate gene selection criteria are presented as Supplementary Data.
Statistical analysis
Descriptive statistics were used for baseline characteristics, safety assessments, PK variables (including C max , AUC 0-∞ , t ½ , CL, and V ss ), and exploratory assessments, including time to progressive disease and tumor response. Comparison between values before and on treatment was performed with paired samples t-test or Wilcoxon signed rank test as appropriate. Assessments of the correlation between dose and fold change in mRNA or pre-mRNA transcript levels were performed using Spearman's rank test. All analyses were performed using SPSS version 12.01 (SPSS, Chicago, IL, USA).
Results
Forty patients (24 male/16 female, median age 61 years [range 45-79]) were screened and enrolled. Patients' characteristics are summarized in Table 1 . Dose levels studied per protocol 10 additional patients (one patient was not evaluable for safety due to rapid disease progression) were enrolled to obtain additional safety and pharmacological data. In this expanded cohort, one patient required dose reduction in Cycle 2 due to the onset of treatment-related hypertension, but no further DLTs were observed at this dose.
In a parallel phase I study with E7107 that explored a day 1 and 8 administration in a 21-day schedule, two patients developed visual problems, leading to a decision taken in January 2009 that all patients were to be taken off medication immediately. In the current study, one patient who was at 4.0 mg/m 2 in his seventh cycle of treatment when taken off the study had started to complain of mild visual alterations, consisting of difficulty in reading and watching television; after treatment discontinuation he subsequently developed Grade-4 blurred vision and central scotomas. Extensive and repeated ophthalmologic investigations, including visual evoked potential measurements, electroretinography, HFA-24-2 visual field analysis, and Goldman perimetry, revealed signs of bilateral optic neuritis. High-dose corticosteroids were prescribed that ultimately led to improvement of the presenting findings with only mild residual symptoms.
Pharmacokinetics
PK data per dose level are summarized in Table 3 . The PK parameters of E7107 were well characterized at all dose levels on days 1 and 15 given the limit of quantification of E7107 in plasma (0.01 ng/mL). Mean C max and AUC showed some variation between patients, but generally were comparable on days 1 and 15 for each patient.
Mean C max and AUC increased in a dose-related manner on day 1 (C max ranged from 
Pharmacodynamics
We were able to demonstrate the biological activity of E7107 with modulation of mRNA and unspliced pre-mRNA of candidate genes in the vast majority of patients (38 of 40) in PBMC samples. These PD analyses revealed that mature mRNA levels of particular candidate genes, TRAPPC4, SLC25A19, and GTF2H1, evidently decreased ( Fig. 1) . Furthermore, the unspliced precursor pre-mRNA levels of DNAJB1 and EIF4A1 clearly showed a marked increase while the mature mRNA levels of these particular genes remained virtually unchanged. These observed changes in relative mRNA and unspliced pre-mRNA levels were clearly dosedependent resulting in an almost linear dose-effect correlation (Fig. 1A) . At the MTD, the mRNA levels of TRAPPC4, SLC25A19, and GTF2H1 showed a 15-to 25-fold decrease, whereas the unspliced pre-mRNA levels of both DNAJB1 and EIF4A1
showed an opposite 10-to 25-fold increase (Fig. 1B) . Notably, comparable results were seen at days 1 and 15 and treatment-induced changes generally peaked at 2-6 hours after end of the bolus infusion and almost completely recovered to baseline levels at 24-48 hours after the end of infusion. These observed PD effects provide proof-of-principle with respect to the expected biological activity of E7107 and further showed that this drug administration schedule resulted in a temporarily, dosedependent, and reversible inhibition of pre-mRNA processing of particular target genes monitored in PBMCs of patients treated with E7107.
Anticancer activity
One patient with acinar pancreatic carcinoma and hepatic metastases had a confirmed partial response lasting 8 months that occurred after he had been taken off study due to the onset of visual disturbances in the parallel study with E7107 (Fig. 2) . During participation in this study, which lasted three cycles, hepatic metastases had regressed after two cycles, but did not constitute a partial response. The first follow-up computed tomography following drug discontinuation showed a decrease in size and number of hepatic metastases constituting a partial response, which was maintained without additional treatment for the next 11 months when asymptomatic RECISTdefined progressive disease was noted. No other partial responses were noted, but stable disease lasting up to seven cycles was observed with no clear correlation between dose administered and duration of disease stabilization. Eight patients presented disease control for more than 3 months.
Discussion
This is the first clinical study that has been performed with the spliceosome inhibitor E7107. Being a phase I study, most emphasis was put on the analysis of safety and tolerability, whereas extensive pharmacological research was done aiming at an optimal assessment of the PK and PD behavior.
In this study, using a 5-minute bolus intravenous administration on days 1, 8, and 15 in a 28-day schedule, DLT was observed at 4.5 mg/m 2 , mainly consisting of gastrointestinal toxicity. Side effects were rapidly reversible in all cases, whereas in subsequent patients treated at next lower dose levels, routinely prescribed antiemetics were largely able to prevent these side effects. Strikingly, hematological toxicity was only very mild and, apart from in one patient, did not lead to either dose reduction or dose delays. A toxicity that was not initially seen in our study was visual disturbance, and the first patient that presented with it was treated in a companion US-based study.
Although recruitment in the present study had been completed, the appearance of this severe toxicity precluded continuation of the two studies. Hence, two patients that were on treatment in our study at that time were immediately discontinued until more knowledge and mechanistic information could be gained on this infrequent side effect.
One of these patients, who was in his seventh cycle of treatment when taken off study, just mentioned the onset of mild visual alterations. Shortly thereafter, this patient developed Grade-4 blurred vision. A full ophthalmologic evaluation resulted in a diagnosis of optic neuritis that improved following treatment with steroids. The nature of this AE and the mechanistic relationship with the mechanism of action of this spliceosome inhibitor is not completely understood. Although none of the other patients complained of any visual disturbance and all the surviving patients that had participated in the study underwent complete ophthalmologic evaluations without any notable findings, we cannot rule out that this AE is attributable to the study drug.
Notwithstanding the fact that this side effect has been demonstrated to be almost completely reversible upon discontinuation of the drug and treatment with steroids, the unpredictable nature of this side effect has prevented further clinical development of E7107.
We have demonstrated that stabilized blood is an easy and excellent source to monitor mRNA and unspliced pre-mRNA levels in surrogate tissue like normal PBMCs upon treatment with spliceosome inhibitors. Evidently, the clear decrease in mRNA levels of particular target genes and the accompanying increase in unspliced pre-mRNA levels of some other candidate genes support the proposition that E7107 functions as a The potential clinical importance of the spliceosome as a target for therapeutic development has been recently highlighted by the identification of mutation of the SF3B1 protein, the target or E7107, in myelodysplastic syndrome with ringed sideroblasts (13-16) and chronic lymphocytic leukemia (CLL) (17) . In CLL the SF3B1 mutation was observed in 15% of cases studied and was associated with 11q deletions and alterations in pre-mRNA splicing. 
